Fidelity Investments’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $265M | Buy |
1,566,995
+385,373
| +33% | +$66.6M | 0.01% | 744 |
|
|
2025
Q4 | $216M | Buy |
1,181,622
+253,739
| +27% | +$35.4M | 0.01% | 841 |
|
|
2025
Q3 | $113M | Sell |
927,883
-48,847
| -5% | -$5.5M | 0.01% | 1129 |
|
|
2025
Q2 | $102M | Sell |
976,730
-270,501
| -22% | -$28.6M | 0.01% | 1109 |
|
|
2025
Q1 | $145M | Buy |
1,247,231
+246,785
| +25% | +$28.1M | 0.01% | 935 |
|
|
2024
Q4 | $84.6M | Sell |
1,000,446
-87,641
| -8% | -$8.06M | 0.01% | 1183 |
|
|
2024
Q3 | $97.8M | Buy |
1,088,087
+185,951
| +21% | +$16.2M | 0.01% | 1112 |
|
|
2024
Q2 | $72.6M | Buy |
902,136
+73,586
| +9% | +$5.45M | ﹤0.01% | 1166 |
|
|
2024
Q1 | $66.1M | Sell |
828,550
-53,477
| -6% | -$4.49M | ﹤0.01% | 1213 |
|
|
2023
Q4 | $70.2M | Sell |
882,027
-976,529
| -53% | -$65.3M | 0.01% | 1160 |
|
|
2023
Q3 | $130M | Sell |
1,858,556
-270,410
| -13% | -$20.2M | 0.01% | 860 |
|
|
2023
Q2 | $153M | Buy |
2,128,966
+764,012
| +56% | +$56.4M | 0.01% | 828 |
|
|
2023
Q1 | $84.2M | Buy |
1,364,954
+630,517
| +86% | +$41.4M | 0.01% | 1042 |
|
|
2022
Q4 | $56.6M | Buy |
734,437
+385,541
| +111% | +$23M | 0.01% | 1211 |
|
|
2022
Q3 | $15.6M | Buy |
348,896
+112,905
| +48% | +$5.64M | ﹤0.01% | 1693 |
|
|
2022
Q2 | $9.04M | Buy |
235,991
+112,971
| +92% | +$3.57M | ﹤0.01% | 2008 |
|
|
2022
Q1 | $5.09M | Sell |
123,020
-305,963
| -71% | -$9.48M | ﹤0.01% | 2363 |
|
|
2021
Q4 | $16.2M | Buy |
428,983
+5,641
| +1% | +$208K | ﹤0.01% | 1916 |
|
|
2021
Q3 | $14M | Buy |
423,342
+72,807
| +21% | +$2.84M | ﹤0.01% | 1983 |
|
|
2021
Q2 | $23.6M | Buy |
350,535
+13,524
| +4% | +$812K | ﹤0.01% | 1780 |
|
|
2021
Q1 | $19.1M | Buy |
337,011
+80,583
| +31% | +$5.67M | ﹤0.01% | 1825 |
|
|
2020
Q4 | $20.9M | Sell |
256,428
-223,675
| -47% | -$16.7M | ﹤0.01% | 1699 |
|
|
2020
Q3 | $34.2M | Sell |
480,103
-95,351
| -17% | -$7.43M | ﹤0.01% | 1343 |
|
|
2020
Q2 | $47.3M | Buy |
575,454
+213,886
| +59% | +$16.5M | 0.01% | 1188 |
|
|
2020
Q1 | $21.3M | Buy |
361,568
+1,128
| +0.3% | +$91.9K | ﹤0.01% | 1377 |
|
|
2019
Q4 | $37.3M | Buy |
360,440
+360,340
| +360,340% | +$14.6M | ﹤0.01% | 1339 |
|
|
2019
Q3 | $2K | Buy |
+100
| New | +$2.57K | ﹤0.01% | 3537 |
|
|
2018
Q4 | – | Sell |
-416,252
| Closed | -$1.44M | – | 3513 |
|
|
2018
Q3 | $1.44M | Sell |
416,252
-565,698
| -58% | -$1.68M | ﹤0.01% | 2425 |
|
|
2018
Q2 | $3.14M | Hold |
981,950
| – | – | ﹤0.01% | 2260 |
|
|
2018
Q1 | $2.41M | Sell |
981,950
-223,862
| -19% | -$670K | ﹤0.01% | 2335 |
|
|
2017
Q4 | $6.75M | Sell |
1,205,812
-310,400
| -20% | -$1.57M | ﹤0.01% | 2075 |
|
|
2017
Q3 | $8.41M | Sell |
1,516,212
-226,800
| -13% | -$1.22M | ﹤0.01% | 2003 |
|
|
2017
Q2 | $9.59M | Sell |
1,743,012
-53,400
| -3% | -$224K | ﹤0.01% | 1960 |
|
|
2017
Q1 | $7.01M | Sell |
1,796,412
-565,213
| -24% | -$2.7M | ﹤0.01% | 2083 |
|
|
2016
Q4 | $15.9M | Sell |
2,361,625
-311,760
| -12% | -$2.19M | ﹤0.01% | 1774 |
|
|
2016
Q3 | $21.1M | Hold |
2,673,385
| – | – | ﹤0.01% | 1651 |
|
|
2016
Q2 | $20.2M | Sell |
2,673,385
-124,046
| -4% | -$1.14M | ﹤0.01% | 1671 |
|
|
2016
Q1 | $24.1M | Sell |
2,797,431
-73,139
| -3% | -$671K | ﹤0.01% | 1577 |
|
|
2015
Q4 | $26.2M | Buy |
+2,870,570
| New | +$25.3M | ﹤0.01% | 1556 |
|
Other funds holding AXSM
VPM
VCM
DTC
Fidelity Investments's AXSM Position: Q1 2026 in Review
Fidelity Investments increased its Axsome Therapeutics (AXSM) stake by 33% in Q1 2026, buying an estimated $66.6M and bringing the position to 1,566,995 shares worth $265M. The position accounts for 0.01% of the portfolio, ranked #744.
Fidelity Investments first reported a position in AXSM in Q4 2015 and has held it in 39 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Fidelity Investments held 1,566,995 shares of Axsome Therapeutics worth $265M as of Q1 2026.
- Fidelity Investments bought 385,373 Axsome Therapeutics shares in Q1 2026, an estimated $66.6M.
- Axsome Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #744 holding.
- Fidelity Investments first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 39 quarters since.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.